Objective: Inaccessibility of the inflammation compartmentalized to the central nervous system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in progressive multiple sclerosis (MS). The double blind combination of Rituximab by IntraVenous and IntraThecAl injection versus placebo in patients with Low-Inflammatory SEcondary progressive MS (RIVITALISE; NCT01212094) trial was designed to answer: (1) Whether an induction dose of intravenous and intrathecal rituximab efficiently depletes CNS B cells? and (2) If so, whether this leads to global inhibition of CNS inflammation and slowing of CNS tissue destruction? Methods: Patients aged 18-65 years were randomly assigned to rituximab or placebo. Protocol-stipulated interim analysis quantified the efficacy of B-cell depletion. Results: The efficacy on cerebrospinal fluid (CSF) biomarkers failed to reach criteria for continuation of the trial. B-cellrelated CSF biomarkers (sCD21 and B-cell activating factor) changed only in the active-treatment arm. While CSF B cells were killed robustly (median À79.71%, P = 0.0176), B cells in CNS tissue were depleted inadequately (~À10-20%, P < 0.0001). Consequently, the T-cell-specific CSF biomarker sCD27 decreased slightly (À10.97%, P = 0.0005), while axonal damage marker, neurofilament light chain did not change. Insufficient saturation of CD20, lack of lytic complement, and paucity of cytotoxic CD56 dim NK cells contribute to decreased efficacy of rituximab in the CNS. Interpretation: Biomarker studies reliably quantified complementary pharmacodynamic effects of rituximab in the CNS, exposed causes for poor efficacy and determined that RIVITALISE trial would be underpowered to measure efficacy on clinical outcomes. Identified mechanisms for poor efficacy are applicable to all CNS-inflammation targeting monoclonal antibodies.
Introduction
Immunomodulatory disease-modifying treatments (DMTs) exert discernable clinical benefit only in patients in early stages of multiple sclerosis (MS), called relapsingremitting MS (RRMS). This lack of clinical efficacy, together with a decreased frequency of clinical relapses and contrast-enhancing lesions (CELs) on brain MRI, has been interpreted as evidence that the vital disability drivers in progressive stages of MS are neurodegenerative, rather than immune mediated. 1 Yet, this conclusion contradicts pathological observations of continued neuroinflammation in patients with progressive MS. 2, 3 An alternative explanation presupposes that pathogenic immune responses in progressive MS are not accessible to current DMTs because of their compartmentalization to central nervous system (CNS) tissue. Indeed, levels of cerebrospinal fluid (CSF) T-cell-and B-cell-specific biomarkers in both progressive MS subtypes (i.e., secondary progressive [SPMS] and primary progressive [PPMS] ) are comparable to those observed in untreated RRMS. 4 However, while immune responses in RRMS consist predominantly of migratory cells detected in the CSF, T, and B cells are mostly embedded in CNS tissue of progressive MS. 4 As compartmentalization (and eventual establishment of tertiary lymphoid follicles in the affected tissue 2 ) results from chronic/repeated activation of adaptive immunity in the particular compartment, it represents a continuous, rather than dichotomized (i.e., compartmentalized or not) process. 4 Consistent with this explanation, functional assays also revealed higher levels of terminal differentiation of intrathecal T cells in progressive MS as compared to RRMS. 5 Thus, lack of therapeutic efficacy of current DMTs in progressive MS could be explained by the combination of advanced CNS compartmentalization and terminal differentiation of pathogenic immune responses. Whether this intrathecal inflammation drives accumulation of clinical disability can be determined only after its effective silencing, which has not been convincingly achieved by any therapeutic strategy thus far, including bone marrow transplantation. 6 Rituximab is a chimeric monoclonal antibody that targets CD20, which is exclusively expressed on pre-B and mature B cells, but not on plasma cells. 7 Clinical trials of intravenous rituximab have demonstrated reductions in MRI and clinical activity in RRMS patients, who, as a group, have opened blood-brain barrier (BBB) in the CNS areas with concentrated inflammation (as measured by CELs on brain MRI). However, rituximab had no efficacy on clinical outcomes in PPMS, who lack CELs, 8 strongly supporting the notion that deficient penetration of the therapeutic antibody to affected CNS tissue may underlie lack of its efficacy.
Therefore, the purpose of the RIVITALISE trial was to investigate whether intrathecal and intravenous administration of rituximab can effectively deplete B cells and inhibit activation of T cells in the CNS compartment of SPMS patients. We report the prespecified interim analysis for the efficacy of B-cell depletion and subsequent mechanistic studies, which revealed causes for differential efficacy of therapeutic antibodies in blood versus CNS compartments.
Materials and Methods
Patients and regulatory approval RIVITALISE is a single center, randomized, double-blind, placebo-controlled study. Patients were prospectively enrolled at the National Institutes of Health (NIH), USA.
Eligible patients were aged 18-65 years and had a diagnosis of MS according to the McDonald's criteria 9 ; had an entry score of 3.0-7.0 on the expanded disability status scale (EDSS); diagnosed as SPMS with lack of MS relapse in the preceding 1 year and nonremitting/sustained progression of disability over 3 months; had not received any DMTs for a period of at least 1 month prior to enrollment; provided informed consent; agreed to commit to the use of an accepted method of birth control. Patients were excluded if they had a diagnosis of PPMS; had past history or signs of immunodeficiency or chronic infections; carried diagnosis of any serious medical disorder; had clinically relevant abnormal blood tests (including IgM and IgG abnormalities); had a positive pregnancy test; had positive CSF or serum quantitative PCR for JC virus. The study was approved by the NIH Institutional Review Board and all patients provided a written informed consent.
Randomization and masking
Patients were randomly assigned to receive rituximab or placebo. Randomization was done by the NIH pharmacy using a table of random numbers. Participants were divided into two strata: younger than 50 years of age (numbered 101-130) and 50 years of age and older (numbered 201-230). At the start of the study (September 2010), the randomization allocation was 1:1. In November 2012, with the protocol amendment to institute a second intrathecal dose at month (Mo) 1.5 after observing inadequate depletion of CSF B cells on the first three treated subjects, the randomization allocation was changed to 2:1. Using a block size of 3: within a block of three the highest two numbers were assigned to rituximab and the lowest number to placebo.
Procedures

Rituximab Investigational New Drug (IND) and selected dosing
Because only approximately 0.1% of intravenous rituximab reaches the CNS compartment under an intact BBB, 10 depletion of B cells in CNS lymphomatous meningitis or CNS lymphoma is significantly higher after intrathecal, in comparison to intravenous administration. 11 Based on literature review (Table S1) , we selected 25 mg as the highest, well-tolerated single intrathecal dose. We amended the protocol to administrate this intrathecal dose twice (6 weeks apart) after we observed inadequate depletion of CSF B cells in the first three subjects.
The selected intravenous induction dose (200 mg 9 2; at Mo 0 and Mo 0.5) is lower than oncology dosing (375 mg/m 2 , weekly 9 4 weeks) or doses previously used for MS (1000 mg 9 2, 2 weeks apart). However, based on literature review 12 , we concluded that this dose (which represented fivefold cost saving) would saturate CD20 and should lead to lasting depletion of B cells from peripheral circulation.
We obtained IND (#107,648) from the Food Drug Administration (FDA) based on the cross-referencing IND application of Dr. Rubenstein (UCSF, San Francisco), which included toxicology and pharmacodynamic data obtained in nonhuman primates. 10 
Trial design
The trial design scheme is shown in Fig. 1A . After premedication with 100 mg IV methylprednisolone, 50 mg of diphenhydramine, 650 mg of acetaminophen, and 1 mg of lorazepam, 20 cc of CSF was withdrawn by lumbar puncture (LP) followed by injection of rituximab (25 mg 
Clinical and imaging evaluation
The clinical evaluations were done every 6 months with EDSS, 13 Scripps Neurological Rating Scale (NRS 14 ) , and MS functional Composite Scale (MSFC 15 ). Neuroimaging evaluation was performed every 6 months with routine spin-echo and gradient-echo T1-weighted images were collected following intravenous administration of 0.1 mmol/kg gadopentetate dimeglumine as described. 16 CELs were quantified according to the consensus of two neurologists with neuroimmunology subspecialty training (B.B. and M.K.) based on precontrast T1-and T2-weighted images.
CSF collection, processing, and immunophenotyping CSF was collected on ice and processed according to written standard operating procedures. 17 A portion of CSF was sent to measure IgG index and presence of oligoclonal bands (OCBs) by isoelectric focusing. Research CSF aliquots were transferred to the Neuroimmunological Diseases Unit (NDU) laboratory, assigned alpha-numeric codes, and centrifuged at 335 g for 10 min at 4°C within 15 min of collection. A minimum of 1 9 10 4 viable CSF cells were analyzed immediately by 12-color flow cytometry to enumerate absolute numbers of 14 subsets of CSF immune cells as described. 17 The CSF supernatant was aliquotted and stored in polypropylene tubes at À80°C until blinded analysis of biomarkers.
Measurement of rituximab concentration and other biomarkers
Electrochemiluminescent assays were developed and optimized to quantify the concentrations of selected biomarkers in the serum and CSF using the Meso Scale Discovery ® (MSD; Meso Scale Diagnostics, Rockville, MD) system as described. 4 The concentration of interleukin (IL)-12p40 was measured by MSD V-plex using the manufacturer's protocol. The assays for rituximab, soluble CD21 (sCD21), sCD27, sCD14, B-cell activating factor (BAFF), and C-X-C motif chemokine 13 (CXCL13) were developed in the NDU laboratory. Neurofilament light protein (NFL) concentration was measured using a commercial ELISA (UmanDiagnostics, Umea, Sweden). All samples excluding IL-12p40 and NFL were run in duplicate. Each assay contained a minimum of two additional reference samples per plate to evaluate intra-and inter-assay reliability. The details of the reagents, manufacturer, detection limits, and intra-assay coefficients of variance are depicted in Table 1 .
In vitro B-cell surface and intracellular rituximab saturation assay B cells were isolated by negative selection (MACS Human B cell Isolation Kit II; Miltenyi Biotec, Auburn, CA) from fresh peripheral blood mononuclear cell (PBMC) of three healthy donors. Purified B cells were then rested overnight at 37°C and 5% CO 2 in X-VIVO 15 media (Lonza) and 1 9 10 5 of B cells were cultured 1, 2, 4 h, or overnight without or with rituximab concentration of either 20 ng/mL (average concentration measured in CSF), 1 lg/mL (average concentration measured in serum), or 10 lg/mL. Subsequently, cells were incubated with fluorescently conjugated antibody against rituximab (MB2A4; AbD Serotec, Oxford, UK) either for surface or intracellular staining, washed, and analyzed on a LSR II flow cytometer (BD Biosciences, San Diego, CA, USA). Mean fluorescent intensity (MFI) was measured on the CD19-gated B-cell population.
In vitro NK cell cytotoxicity assay (H4A3/H4B4; BD Biosciences) present during co-culture period, in the presence of 20 ng/mL or 1 lg/mL of rituximab. Control wells included effectors (NK cells only) without targets (B cells or K562 cells) and targets without effectors. MHC-I-negative K562 cells served as a positive control for NK cytotoxicity. After 6 h, the cells were stained for surface expression of CD19 (SJ25-C1; Life Technologies), dead cells (LIVE/DEAD fixable dead cell stain kit; Life Technologies), CD56 (B159; BD Biosciences) and intracellular perforin (delta G9; eBiosciences, San Diego, CA, USA) and analyzed by flow cytometer. NK cell degranulation (CD107a/b + ) and perforin release (perforin À ) were compared between NK cells cultured without and with different targets. Absolute numbers of live CD19 + B cells were acquired using fluorescent beads for normalization. 5 Cytotoxicity was calculated as: % cytotoxicity = (live B cell numbers in the sample/live B cell numbers in B cell control) 9 100.
In vitro B-cell cytotoxicity assay
To determine whether memory B cells (dominant B cell subtype in the CSF) are more resistant to rituximab-driven depletion than na€ ıve B cells, and also whether B cells under rituximab treatment are predominantly killed by complement-dependent cytotoxicity (CDC) versus antibody-dependent cellular cytotoxicity (ADCC), 1 9 10 5 of purified na€ ıve B cells and memory B cells were cultured 4 h with rituximab (1 lg/mL) or a control antibody (daclizumab 1 lg/mL; Roche) in the presence of 50% of serum (SST TM Serum Separation Tubes; BD Vacutainer â , Franklin Lakes, NJ, USA) or 50% of pooled MS CSF samples (to assure reproducible conditions for all experiments). Subsequently, cells were incubated with fluorescently conjugated antibody against CD19 and dead cells, and analyzed by a flow cytometer. Live B cells were gated on CD19 and dead cell staining, and their relative numbers were calibrated with fluorescent beads. 5 
Statistical analyses
Repeated measures analysis of variance (ANOVA) was used to evaluate the change in biomarker and clinical score variables from baseline to the follow-up visits. For both CSF and blood markers, the average of Mo -12 and Mo 0 was used as baseline. For clinical score, the average of Mo -12, Mo -6, and Mo 0 was used as baseline. Dunnett's method was used to adjust for multiple 
Results
From September 14, 2010 to February 20, 2015, 43 patients were assessed for eligibility and 27 patients were randomly assigned to receive either rituximab (n = 18) or placebo (n = 9; Fig. 1B ). Of the 18 patients assigned to a treatment group, 14 received at least two doses of intrathecal rituximab and were included in the interim analysis as per protocol. Baseline characteristics were similar for both groups (Table 2) .
Selected dosing leads to measurable CSF concentrations of free rituximab, sustained for several months Free (i.e., non-cell bound) rituximab levels were measured by sensitive electrochemiluminescence ELISA. In the serum, we observed a significant increase in rituximab levels 1 day after each intravenous dose (Mo 0.03 and Mo 0.53) in the active-treatment patients only ( Fig. 2A) . Consequently, serum rituximab levels were significantly elevated at months 0.5, 1.5, and 3, but had returned to baseline at Mo 12. Measured serum levels of free rituximab in this study were lower (average 1036 ng/mL, median 822 ng/mL) in comparison to reported levels of rituximab under oncology dosing (i.e., 375 mg/m 2 IV 9 4; C max 486 lg/mL). 18 Lower concentrations can be explained by ≥fivefold lower intravenous dose in this protocol and by the fact that postinfusion concentrations were measured >12 h after completion of the infusion (which is expected to significantly diminish C max based on reported serum rituximab half-life of 76.3 h 18 ). Rituximab serum concentrations also significantly increased after intrathecal dose administrated at Mo 12 ( Fig. 2A) , consistent with neonatal Fc-receptor (n-FcR)-mediated efflux of CSF immunoglobulins to the blood. 11, 19 In the CSF, we observed a significant increase in rituximab levels in the active-treatment cohort only, at months 1.5, 3, and 12 ( Fig. 2B) . CSF rituximab levels (average 24 ng/mL, median 21 ng/mL) were approximately 50-fold lower in comparison to serum levels, which still represent a 20-fold increase in bioavailability of rituximab in the intrathecal compartment in comparison to intravenous administration only (i.e., 2% of serum values measured in current study vs. 0.1% of serum values achievable without intrathecal dosing 10 ).
While depletion of peripheral B cells is complete and lasting, depletion of CSF B cells is incomplete and transient
Consistent with the measurable levels of cell-free rituximab in both compartments, we observed significant depletion of blood and CSF B cells from patients on active therapy only (Fig. 2C, D) . While B-cell depletion from the blood was almost complete (median À98.79% at Mo 3; P < 0.0001) and sustained for at least 12 months (at which point blood levels started to repopulate with na€ ıve B cells), CSF B-cell levels decreased significantly only at Mo 1.5 (median À79.71%; P = 0.0176). Interestingly, the efflux of intrathecally administered rituximab to systemic circulation at Mo 12.03 (i.e., one day after intrathecal injection) lead to a measurable decrease in the absolute numbers of blood B cells (Fig. 2C) , demonstrating that the resultant concentration of rituximab in the serum (median 304 ng/mL) has a robust B-cell-depleting efficacy in the peripheral circulation. 20 
Significantly greater and lasting increase of serum BAFF in comparison to mild/transient increase in CSF BAFF levels is consistent with partial depletion of CNS B cells
As BAFF is consumed by B cells and plasma cells, we observed significant increase (median +141.86%; P < 0.0001) at Mo 3 in serum BAFF levels in the activetreatment group only (Fig. 3A) consistent with published literature. 21 Although CSF levels of BAFF also increased (by median of +8.39% at Mo 3, P = 0.0164), it did not reach the protocol-stipulated predetermined threshold of at least 50% increase, required for study continuation.
CSF levels of CXCL13 are not affected by intrathecal rituximab therapy
In the serum, we observed a significant decrease in the levels of CXCL13 at Mo 1.5 (median À31.51%, P = 0.0039) and Mo 3 (median À58.43%, P = 0.0014), but the CSF levels of this chemokine remained unchanged in the rituximab-treated patients, even in those with the highest CSF CXCL13 levels (Fig. 3B) . This second protocol prespecified criterion for continuation of study was therefore not fulfilled either.
Measured decreases in B-cell-specific marker, sCD21, corroborates significantly higher efficacy of B-cell-depletion in peripheral as compared to CNS CD21 is a B-cell-specific shed surface marker, which is expressed on 100% of na€ ıve B cells, but its surface expression decreases during the B-cell differentiation process. 4 Therefore, while it is not a sensitive diagnostic marker (i.e., normal CSF sCD21 levels do not rule out an increase in intrathecal B cells), its cell specificity for B cells makes it an excellent pharmacodynamic marker of B-cell-depleting therapies. We observed a significant decrease in serum sCD21 levels (median of À56.02% at Mo 0.5; P < 0.0001, median of À32.69% at Mo 3; P < 0.0001; Fig. 3C ) and a lower, but still highly significant, decrease in CSF sCD21 levels (maximum decrease with median of À28.02% at Mo 3, P < 0.0001). Serum levels of sCD21 returned to pretreatment baseline values at Mo 12, consistent with observed repopulation of the blood by na€ ıve B cells. CSF levels of sCD21 also returned to pretreatment baseline at Mo 12.
The ratio of sCD21 per B cell in the CSF, which is a measure of B cells compartmentalized to the CNS tissue, 4 increased to median of 424.12% at Mo 1.5 (P = 0.0045; data not shown). This result demonstrates that intrathecal rituximab preferentially eliminated the mobile (CSF) pool of B cells, while CNS tissue-embedded B cells were not affected.
B cells under rituximab therapy are killed by CDC, and to a lesser degree by ADCC. Low CSF levels of rituximab and lytic complement and low proportion of cytotoxic CD56 dim NK cells collectively underlie poor B-cell depletion in the CNS
The afore-mentioned experiments demonstrated that despite the lasting measurable concentrations of free rituximab in the CSF, intrathecal B cells were only partially and transiently depleted. We considered and experimentally tested several possible explanations of this phenomenon: (1) Because of proportional predominance of immunoregulatory CD56 bright NK cells in the CSF as compared to blood 17 , we asked whether CD56 dim and CD56 bright NK cells differ in their ability to mediate ADCC of B cells under rituximab therapy; (2) Because of predominance of memory B cells in the CSF, 22 we asked whether memory B cells are more resistant to rituximab-driven depletion than na€ ıve B cells; and finally, (3) Because of the controversy whether B cells under rituximab treatment are predominantly killed by CDC versus ADCC, 23 we compared these two cytotoxic modalities side by side (Fig. 4) .
We observed that average measured CSF concentrations of rituximab (20 ng/mL) did not saturate CD20 on B cells, while the average measured concentration in the blood (1 lg/mL) did (Fig. 4A left panel) . Our data also demonstrated that intravenous dose selected for this trial (i.e., 200 mg 9 2) may be closer to the optimal dose for non-oncologic indications than standardly utilized 1000 mg 9 2 dose because the 10 lg/mL concentration (which is still below peak concentrations achievable by oncology dosing 18 ) paradoxically decreased the measurable rituximab concentration on the surface of B cells, due to higher internalization of CD20/rituximab complexes (Fig. 4A right panel Fig. 4B ; right panel), which was significantly higher (P = 0.0001) for blood (1 lg/mL) in comparison to CSF (20 ng/mL) rituximab concentrations.
Nevertheless, the most efficient killing of rituximabcoated B cells was observed by CDC in the serum, but not CSF (Fig. 4C) . Killing was comparable for na€ ıve and memory B cells (P = 0.0453 and 0.0223, respectively). In contrast, when B cells were pretreated with control antibody (daclizumab; which is a nondepleting humanized antibody against CD25) 24 , B cell killing was not observed (Fig. 4C) . Combination of intravenous and intrathecal rituximab leads to significant, but quantitatively modest inhibition of MSrelated intrathecal T-cell-mediated inflammation, which does not affect CSF biomarker of axonal damage
Because an early termination of clinical trials is often associated with the ambiguity of a potential final outcome of fully executed study, we investigated the effect of rituximab on three additional CSF biomarkers that have been previously validated as biomarkers of MS-related inflammation (i.e., sCD27, a biomarker of activated T cells 4 ; IL-12p40 mainly produced by activated cells of myeloid lineage and by activated B cells 4 ) or axonal damage (i.e., neurofilament light chain; NF-L 25 ; data not shown). In rituximab-treated patients, we observed significant inhibition of IL-12p40 (median À42.42%, P = 0.0110 at Mo 3) as well as sCD27 (À10.97%, P = 0.0005 at Mo 3; À29.28%, P = 0.0024 at Mo 12), in the active therapy group only. On the other hand, CSF levels of NF-L remained unchanged.
Clinical scores worsened during the observation period for both placebo and treated groups
Early termination makes the acquired clinical and imaging data insufficient (i.e., underpowered) for reliable analyses. Therefore, we present descriptive statistics (Fig. 5 ) and conclude that clinical scales were comparable between placebo and rituximab groups, while CEL counts on brain MRI remained low with trend toward their inhibition on active treatment.
Discussion
Current immunomodulatory treatments have limited efficacy in progressive MS, especially when patients no longer experience relapses and CELs, 8, 26 although CNS inflammation remains quantitatively identical to inflammation in RRMS. 4 This apparent discrepancy has two possible explanations, not mutually exclusive: 1. Compartmentalized CNS inflammation in progressive MS 4 is not amenable to inhibition by current DMTs; and/or 2. The CNS inflammation, while present, no longer drives clinical disability. Though we discussed evidence supporting the first alternative 2, 4, 5 in the introduction, the second alternative can be proven only by achieving a substantial inhibition of the intrathecal inflammation (ideally its complete normalization) and observing no efficacy on clinical outcomes in adequately powered studies.
Consequently, the rationale behind the RIVITALISE trial rested in the ability of intravenous rituximab to significantly decrease CSF B-cell and T-cell counts 27 and inhibit MS relapses 28 in patients with RRMS who have opened BBB, but having no effect on CSF B-cell counts 29 and disability 8 in PPMS patients, who have intact BBB. Therefore, we hypothesized that combination of intravenous and intrathecal administration of rituximab will lead to an effective depletion of B cells from both systemic and CNS compartments, leading to inhibition of all MS-related inflammation. Only if this hypothesis was correct, we could answer the most important question: whether successful inhibition of intrathecal inflammation in progressive MS decreases CNS tissue destruction and accumulation of disability. It is with this understanding that we incorporated an interim analysis for the efficacy of B-cell depletion in the RIVITALISE trial and related trial stopping criteria for futility.
The main limitation of this approach is uncertainty whether restricted numbers of patients in the interim analysis can provide unequivocal evidence for intrathecal efficacy. While we acknowledge this drawback, we believe that our selection of multiple, biologically complementary biomarkers of B-cell lineage and our measurements of congruent results for all of these biomarkers provide confidence to our conclusion that rituximab has significantly lower efficacy in the CNS, as compared to blood.
Use of complementary biomarkers that are either specifically released by B cells (sCD21), or enriched in meningeal lymphoid follicles (CXCL13) 2 where it is predominantly produced by myeloid cells and activated B cells, 4 or that are consumed by B cells and plasma cells (BAFF), provided unequivocal evidence for almost complete and lasting depletion of B cells from the peripheral blood, but only partial and transient depletion of B cells from the intrathecal compartment. The treatment-induced rise in sCD21/CSF B-cells ratio indicates that B cells were insufficiently depleted from CNS tissue, 4 which is supported by the limited diffusion of rituximab in the brain parenchyma. 30 Comparing the efficacy of CDC versus ADCC on the same mixture of effector/target cells identified CDC as dominant form of B-cell killing by rituximab. These results are consistent with published observations that polymorphism in the complement component C1qA correlates with the efficacy of rituximab in B-cell malignancies 31 and that addition of fresh frozen plasma augments therapeutic efficacy of rituximab by providing additional complement. 32 The lack of components capable to assemble the lytic terminal complement complex in the CNS, together with a lower ADCC underlies the poor CNS efficacy of rituximab in the subjects with intact BBB (Fig. 6) 24 However, because the NK cells integrate inhibitory (i.e., MHC-I/killer inhibitory receptors) and activating (e.g., Fc receptor-and cytokinemediated) signals when deciding to kill, the lack of CD20 saturation, as well as lower rituximab-induced "cytokine storm" likely further inhibits ADCC in the CSF (Fig. 6) .
The observed insufficient depletion of B cells from the CNS in RIVITALISE trial is supported by in vivo observations from neurological diseases such as anti-NMDA encephalitis, where complement-binding (i.e., IgG1) anti-NMDA antibodies present in large quantities in the CSF, and CNS tissue do not cause cytotoxicity, but rather lead to internalization of NMDA molecules from the neuronal surface. 33 In contrast, opening of the BBB (seen in RRMS patients and CNS B-cell malignancies) that produces focally high concentrations of the complement may be a prerequisite for efficient depletion of B cells under rituximab therapy, but also to cause antibody-mediated CNS damage under pathological conditions such as neuromyelitis optica.
This conclusion has far-reaching consequences: as long as efficacy of therapeutic antibodies depends on CDC or ADCC, administration of a drug to the CSF will not lead to a substantial efficacy under situations with closed BBB. Therefore, while administration of antibodies to the CSF is feasible and relatively well tolerated (and potentially can be used as long-term therapy via CSF pumps), antibodymediated efficacy needs to rely on different mechanism(s) to exert a potent therapeutic effect in CNS diseases with intact BBB. We expect that supplementing complement in addition to therapeutic antibodies may not be a viable option due to possible side effects to vital CNS tissue. Our results also highlight important role for n-FcR mediated active efflux of antibodies from the intrathecal compartment to blood and suggest that engineered modifications of antibody structure that minimize its binding to n-FcR can greatly increase achievable concentrations and half-life of intrathecally administered antibodies in the CSF/CNS, while limiting (often undesired) systemic exposure.
In summary, implementation of biomarker studies to RIVITALISE trial led to its early termination based on the assessment that lower-than-expected depletion of intrathecal B cells and resultant limited inhibition of MSrelated inflammation is insufficient to translate to potential clinical efficacy in small Phase II trial. This study provides proof that incorporating biomarker assays that measure pharmacodynamic effects on the crucial pathogenic pathways in the CNS tissue makes drug development more efficient, by providing essential information for the funders to decide whether to proceed to expensive Phase III trial(s) and how to power these trials properly in order to assure positive results.
